Susquehanna International Group
PCVX icon

Susquehanna International Group’s Vaxcyte PCVX Stock Holding History

Susquehanna International Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Buy
275,300
+261,000
+1,825% +$14.2M ﹤0.01% 2490
2025
Q4 		$660K Sell
14,300
-44,400
-76% -$1.99M ﹤0.01% 8170
2025
Q3 		$2.11M Buy
58,700
+7,300
+14% +$242K ﹤0.01% 5665
2025
Q2 		$1.67M Sell
51,400
-81,200
-61% -$2.66M ﹤0.01% 6181
2025
Q1 		$5.01M Sell
132,600
-50,800
-28% -$4.06M ﹤0.01% 3649
2024
Q4 		$15M Buy
183,400
+61,800
+51% +$6.14M ﹤0.01% 2163
2024
Q3 		$13.9M Sell
121,600
-4,900
-4% -$442K ﹤0.01% 2204
2024
Q2 		$9.55M Buy
126,500
+71,000
+128% +$4.83M ﹤0.01% 2543
2024
Q1 		$3.79M Buy
55,500
+1,700
+3% +$118K ﹤0.01% 4102
2023
Q4 		$3.38M Buy
53,800
+40,200
+296% +$2.09M ﹤0.01% 4378
2023
Q3 		$693K Sell
13,600
-9,200
-40% -$454K ﹤0.01% 7470
2023
Q2 		$1.14M Sell
22,800
-55,600
-71% -$2.64M ﹤0.01% 6378
2023
Q1 		$2.94M Sell
78,400
-98,200
-56% -$4.17M ﹤0.01% 4371
2022
Q4 		$8.47M Buy
176,600
+104,200
+144% +$4.09M ﹤0.01% 2492
2022
Q3 		$1.74M Buy
72,400
+23,200
+47% +$588K ﹤0.01% 5225
2022
Q2 		$1.07M Buy
49,200
+29,700
+152% +$687K ﹤0.01% 6359
2022
Q1 		$471K Buy
19,500
+10,600
+119% +$232K ﹤0.01% 9150
2021
Q4 		$212K Sell
8,900
-3,100
-26% -$72.1K ﹤0.01% 11322
2021
Q3 		$304K Buy
+12,000
New +$291K ﹤0.01% 10576
2021
Q2 		– Sell
-16,700
Closed -$330K – 13070
2021
Q1 		$330K Buy
+16,700
New +$420K ﹤0.01% 10400

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's PCVX Position: Q1 2026 in Review

Susquehanna International Group increased its Vaxcyte (PCVX) stake by 38% in Q1 2026, buying an estimated $703K and bringing the position to 47,073 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #5463.

Susquehanna International Group first reported a position in PCVX in Q2 2021 and has held it in 20 quarters since. The position peaked at $12M in Q1 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Susquehanna International Group held 47,073 shares of Vaxcyte worth $2.74M as of Q1 2026.
  • Susquehanna International Group bought 12,957 Vaxcyte shares in Q1 2026, an estimated $703K.
  • Vaxcyte made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5463 holding.
  • Susquehanna International Group first reported a position in Vaxcyte in Q2 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's Vaxcyte position peaked at $12M in Q1 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.